The Shotlee Journal
Browse Shotlee articles about GLP-1 Medications.
Showing 9 / 939 GLP-1 Medications articles
Jessica Layeux spent 15 months on Zepbound with minimal weight loss, joining 1 in 10 clinical trial non-responders who lose less than 5% body weight. Scientists are investigating genetics, hormones, and other factors behind why these popular GLP-1 drugs don't work for everyone. This guide explains the science and next steps for patients.
Zydus Lifesciences and Lupin are teaming up to bring Semaglutide injection to India, positioning it as a rival to Ozempic for type 2 diabetes and chronic weight management. Marketed by Zydus with a user-friendly reusable pen, this GLP-1 therapy offers new options for adults with poor glycemic control or obesity-related conditions. Here's what patients need to know about this launch.
Layla Taylor, star of The Secret Lives of Mormon Wives, has stepped away from GLP-1 medications after using them as an unhealthy crutch for her lifelong eating disorder. Ahead of season 4, she opens up about hidden side effects like aching joints, falling hair, and constant fatigue that signaled her body was breaking down. Her story underscores the importance of monitoring GLP-1 use, especially with pre-existing conditions.
Two women were rushed to the hospital and intubated after receiving peptide injections at a Las Vegas anti-aging festival. Nevada regulators fined providers $35,000 for unlicensed practice and wholesaling. This incident highlights the dangers of unregulated peptides promoted for anti-aging.
The surge in GLP-1 drug use among 12% of Americans is upending the food industry, with sauce and spice makers like Bachan's and Tapatio attracting high-value deals. As these medications dull taste buds and spur lean protein consumption, condiment companies are seeing explosive growth. Fast-food giants face billions in losses while flavor enhancers thrive.
Eli Lilly, maker of Mounjaro and Zepbound, has discovered critical impurities in counterfeit tirzepatide versions mixed with vitamin B12. These compounded drugs pose unknown risks due to chemical reactions and lack of FDA oversight. With one in eight Americans using GLP-1s, experts urge sticking to approved medications.
A quote from The Economist's Style Guide warns against calling anything a panacea—yet GLP-1 drugs for type 2 diabetes and obesity are now eyed by healthy individuals for longevity. Is their time as a miracle cure finally here? This guide weighs the excitement against expert caution and real-world considerations.
A groundbreaking study reveals Wegovy carries a fivefold higher risk of vision-threatening ischemic optic neuropathy compared to Ozempic. Analyzing millions of FDA reports, researchers link the risk to semaglutide's higher doses in Wegovy. Amid rising lawsuits, patients need to weigh benefits against potential eye health dangers.
Weight loss injections such as Mounjaro and Wegovy, popular GLP-1 inhibitors, come with side effects impacting one in 10 users, primarily digestive issues like nausea and diarrhea. The British Heart Foundation highlights risks including pancreatitis, vision loss, and nutritional deficiencies. Understanding these helps patients manage treatment safely.
